摘要
目的探讨一类新的PI3K/Akt抑制剂CCT128930对人脐静脉血管内皮细胞(HUVEC)增殖与血管生成的影响。方法采用MTT法检测CCT128930对HUVEC存活的影响;流式细胞术分析细胞周期变化;AnnexinⅤ-FITC试剂盒检测细胞凋亡;体外小管形成实验观察CCT128930对HUVEC体外小管形成的影响;免疫印迹法检测蛋白表达水平。结果CCT128930可通过阻滞细胞于G1期而抑制HUVEC的增殖,且抑制作用呈剂量依赖性,但对HUVEC的凋亡无影响;HUVEC经CCT128930处理后,体外小管形成能力受到明显抑制;低浓度的CCT128930抑制内皮细胞中VEGF的表达,但对Akt的磷酸化水平无影响。结论 CCT128930能够抑制HUVEC的增殖与血管生成,其抑制血管生成活性可能与其调控VEGF的表达水平相关。
Aim To assess the effects of CCT128930,an inhibitor of Akt,on cell proliferation and angiogenesis in cultured human umbilical vein endothelial cells(HUVECs) in vitro.Methods Cell viability was detected by MTT assay,cell cycle was analyzed by flow cytometry,AnnexinⅤ-FITC apoptosis detection kit was used to detect apoptosis of cells,and protein expression was examined by Western blot.Results MTT and cell cycle analysis results indicated that CCT128930 inhibited the growth of HUVECs in a dose-dependent manner,and arrested cell cycle progression at the G1 phase.In addition,tube formation of HUVECs was markedly inhibited by CCT128930.Western blot results showed that anti-tube formation activity of lowdose CCT128930 was not related with the PI3K / Akt pathway,and suppressing the expression of VEGF in HUVECs may be invlolved in this process.Conclusion CCT128930 exerts anti-angiogenic activity in HUVECs and the inhibition of VEGF expression potentially contributes to its anti-angiogenic activity.
出处
《中国药理学通报》
CAS
CSCD
北大核心
2012年第10期1413-1416,共4页
Chinese Pharmacological Bulletin
基金
国家自然科学基金资助项目(No 30800422)
山东省自然科学基金资助项目(No ZR2011HQ034)